Jianyun Nie
519 Kunzhou Road
Kunming, 650118, China
Kunming, 650118, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
ACOD1 enhances the ferroptosis resistance of tumor-associated macrophages through the KEAP1/NRF2 axis and promotes triple-negative breast cancer progression.
Journal: Pathology, research and practice
Published: June 17, 2026
Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.
Journal: Biomolecules & biomedicine
Published: April 23, 2026
Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis.
Journal: Frontiers in immunology
Published: April 09, 2026
NFYA-Mediated TTK Up-Regulation Drives Fast Cell Cycle Progression and Its Inhibition Leads to Mitotic Catastrophe in Triple Negative Breast Cancer.
Journal: Cancers
Published: March 27, 2026
The multifaceted roles of mitochondria and their therapeutic transformation: a new perspective on triple-negative breast cancer treatment.
Journal: Frontiers in oncology
Published: March 24, 2026
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
Journal: BMJ (Clinical research ed.)
Published: March 16, 2026
STAT3 inhibitor in oncology: a trial-based analysis of translational challenges and evolving therapeutic paradigms.
Journal: Frontiers in oncology
Published: February 03, 2026
Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: January 08, 2026
Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.
Journal: Cancer communications (London, England)
Published: December 09, 2025
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 14, 2025
Construction and validation of a predictive model of pathological complete response combined with MRI and tumor indicators for HER2-positive breast cancer after neoadjuvant targeted therapy.
Journal: Oncology letters
Published: November 05, 2025
Last Updated: 09/26/2026